CALIFORNIA PACIFIC MEDICAL CENTER
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $11.3M
- Transactions
- 1,034
- Companies
- 40
- Average per transaction
- $10,969
Who reported the payments
| Merck | $5,456,805 |
| Genentech, Inc. | $946,030 |
| Gilead | $905,785 |
| AstraZeneca | $644,956 |
| Modernatx, Inc. | $619,875 |
| Edwards Lifesciences | $375,052 |
| Jenavalve Technology, Inc. | $317,007 |
| Amgen | $219,283 |
| E.r. Squibb & Sons, L.L.C. | $202,543 |
| Regeneron | $172,586 |
| AbbVie | $145,773 |
| PTC Therapeutics, Inc. | $109,449 |
| Novocure Inc. | $106,858 |
| Intercept Pharmaceuticals, Inc. | $106,110 |
| Medtronic | $104,454 |
| Tesaro, Inc. | $88,486 |
| Mallinckrodt Enterprises LLC | $66,664 |
| Pfizer | $63,570 |
| Partner Therapeutics, Inc. | $55,251 |
| Eli Lilly | $53,257 |
| Stryker | $51,415 |
| Astellas Pharma Global Development | $44,019 |
| Takeda Pharmaceuticals U.S.A., Inc. | $38,040 |
| Boston Scientific | $33,678 |
| CSL Behring | $32,761 |
| Amylyx Pharmaceuticals, Inc. | $28,799 |
| Argenx US, Inc. | $25,955 |
| Array Biopharma Inc | $25,857 |
| Taiho Oncology, Inc. | $25,459 |
| Vanda Pharmaceuticals Inc. | $22,752 |
| Incyte Corporation | $21,400 |
| Astrazeneca UK Limited | $21,305 |
| Biohaven Pharmaceutical Holding Company Ltd. | $20,803 |
| Orion Corporation | $15,492 |
| Penumbra, Inc. | $15,480 |
| Mitsubishi Tanabe Pharma Development America, Inc. | $15,250 |
| Bristol Myers Squibb | $13,750 |
| Roche Products Limited | $13,011 |
| F. Hoffmann-la Roche AG | $11,439 |
| Sirtex Medical Inc | $10,755 |